
Sign up to save your podcasts
Or


There's big money to be make in drug development. But is that necessarily a good thing?
Pharmaceutical companies capitalize on years of R&D work with exclusive patents. Approved drugs typically commercialize in developed markets that can support higher pricing through mature insurance reimbursement networks.
Yet serious diseases don't only occur in the developed world. Billions of people in developing economics need treatments as well. And they're often not able to afford the hundreds of thousands of dollars it costs for innovative approaches such as CRISPR gene editing or CAR-T gene therapy.
There's currently an unmet market need for treating serious chronic conditions like Alzheimer's Disease in a way that isn't prohibitively expensive. And sometimes, it's worth veering from the herd and thinking about big problems in an entirely new way.
In today's 7investing podcast, 7investing lead advisors Simon Erickson and Dana Abramovitz chat with Mei Mei Hu, the co-founder and CEO of Vaxxinity (Nasdaq: VAXX). Vaxxinity is using a disruptive synthetic peptide platform to provide cheaper, safer, more convenient, and more effective medicines for chronic diseases like Alzheimer's and Parkinson's Disease. It is also developing a late-stage vaccines for the prevention of COVID.
In the conversation, Mei Mei describes how Vaxxinity's technology is "turning the human body into its own drug factory" to avoid the excessive costs and immune response issues of traditional monoclonal antibodies. She discusses their unique approach to clinical trials, the progress their making in their programs, and what it's like to be the CEO of a newly-public company.
Publicly-traded companies mentioned in this interview include United Biomedical and Vaxxinity. 7investing’s advisors or its guests may have positions in the companies mentioned.
Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.
Start your journey toward's financial independence: https://www.7investing.com/subscribe
Stop by our website to level-up your investing education: https://www.7investing.com
Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw
Start a free YCharts trial: https://ycharts.com/store/start_trial_register?utm_source=7Investing&utm_medium=blog&utm_campaign=2022+7Investing
Follow us:
► https://www.facebook.com/7investing
► https://twitter.com/7investing
► https://instagram.com/7investing
By 7investing4.1
8787 ratings
There's big money to be make in drug development. But is that necessarily a good thing?
Pharmaceutical companies capitalize on years of R&D work with exclusive patents. Approved drugs typically commercialize in developed markets that can support higher pricing through mature insurance reimbursement networks.
Yet serious diseases don't only occur in the developed world. Billions of people in developing economics need treatments as well. And they're often not able to afford the hundreds of thousands of dollars it costs for innovative approaches such as CRISPR gene editing or CAR-T gene therapy.
There's currently an unmet market need for treating serious chronic conditions like Alzheimer's Disease in a way that isn't prohibitively expensive. And sometimes, it's worth veering from the herd and thinking about big problems in an entirely new way.
In today's 7investing podcast, 7investing lead advisors Simon Erickson and Dana Abramovitz chat with Mei Mei Hu, the co-founder and CEO of Vaxxinity (Nasdaq: VAXX). Vaxxinity is using a disruptive synthetic peptide platform to provide cheaper, safer, more convenient, and more effective medicines for chronic diseases like Alzheimer's and Parkinson's Disease. It is also developing a late-stage vaccines for the prevention of COVID.
In the conversation, Mei Mei describes how Vaxxinity's technology is "turning the human body into its own drug factory" to avoid the excessive costs and immune response issues of traditional monoclonal antibodies. She discusses their unique approach to clinical trials, the progress their making in their programs, and what it's like to be the CEO of a newly-public company.
Publicly-traded companies mentioned in this interview include United Biomedical and Vaxxinity. 7investing’s advisors or its guests may have positions in the companies mentioned.
Welcome to 7investing. We are here to empower you to invest in your future! We publish our 7 best ideas in the stock market to our subscribers for just $49 per month or $399 per year.
Start your journey toward's financial independence: https://www.7investing.com/subscribe
Stop by our website to level-up your investing education: https://www.7investing.com
Join the 7investing Community Forum: https://discord.gg/6YvazDf9sw
Start a free YCharts trial: https://ycharts.com/store/start_trial_register?utm_source=7Investing&utm_medium=blog&utm_campaign=2022+7Investing
Follow us:
► https://www.facebook.com/7investing
► https://twitter.com/7investing
► https://instagram.com/7investing

3,219 Listeners

3,368 Listeners

944 Listeners

965 Listeners

399 Listeners

1,942 Listeners

1,452 Listeners

192 Listeners

1,039 Listeners

2,118 Listeners

556 Listeners

349 Listeners

220 Listeners

316 Listeners

1,421 Listeners